Dynulta 2500 mg (Sucroferric oxyhydroxide)

Product Overview

Dynulta 2500 mg is a prescription phosphate binder manufactured by Emcure Pharmaceuticals Ltd. It contains sucroferric oxyhydroxide, a medication that reduces the absorption of dietary phosphate in the gastrointestinal tract. The drug is specifically indicated for patients with chronic kidney disease who require long‑term management of elevated serum phosphate levels. Each strip includes six tablets, and the product is marketed in pack sizes of 30, 60, and 90 tablets, offering flexibility for chronic therapy.

What is Dynulta 2500 mg

Dynulta 2500 mg refers to a tablet strength of 2500 milligrams of sucroferric oxyhydroxide per unit. The active ingredient belongs to the class of phosphate binders that act locally in the gut to sequester phosphate ions. Because the binding occurs within the intestines, the medication does not rely on systemic absorption, making it suitable for patients with reduced kidney function. The formulation is designed to be taken with meals to maximize interaction with dietary phosphate.

Uses and Benefits

The primary therapeutic use of Dynulta is to lower blood phosphate concentrations in individuals with end‑stage renal disease. Elevated phosphate levels can lead to vascular calcification, bone disease, and secondary hyperparathyroidism. By binding phosphate in the intestine, Dynulta helps prevent these complications when used together with dietary counseling and regular laboratory monitoring. Clinical studies have demonstrated that consistent use can maintain target phosphate ranges, reduce the need for more aggressive interventions, and improve overall mineral balance in chronic kidney disease patients.

How It Works

Sucroferric oxyhydroxide particles carry a positive charge that attracts negatively charged phosphate ions present in food. This electrostatic attraction forms an insoluble complex that is excreted in the feces. Because the binding process is confined to the gastrointestinal lumen, the drug does not enter the bloodstream in significant amounts, which minimizes systemic exposure and reduces the risk of drug‑drug interactions. The mechanism provides a localized, dose‑dependent reduction in phosphate absorption, allowing clinicians to tailor therapy based on individual patient needs.

Dosage Guidelines

Typical initial dosing for Dynulta 2500 mg is one tablet taken with each main meal, three times daily. The exact number of tablets may be adjusted based on baseline serum phosphate levels, dietary phosphate intake, and the prescribing physician’s assessment. Patients should not exceed the recommended daily dose and must follow the instructions printed on the label or those given by their healthcare provider. Regular laboratory tests are essential to evaluate the effectiveness of therapy and to modify the dose as needed.

Side Effects

Most users experience mild gastrointestinal symptoms such as constipation, nausea, or abdominal discomfort. Dark stools are a common, benign occurrence due to the iron‑containing component of the formulation. Less frequently, patients may report headache or transient dizziness. If severe abdominal pain, persistent vomiting, or signs of an allergic reaction (such as rash, itching, or swelling) develop, medical attention should be sought promptly. For additional information on phosphate binder safety, refer to the NIH Kidney Disease resource. Any unexpected adverse events should be reported to the prescribing clinician.

Warnings and Precautions

Dynulta is contraindicated in patients with known hypersensitivity to sucroferric oxyhydroxide or any excipients in the tablet formulation. Caution is advised in individuals with a history of bowel obstruction, chronic constipation, or electrolyte disturbances, as the medication may exacerbate these conditions. The product should be stored at room temperature, protected from moisture and heat, and kept out of reach of children. Do not use after the expiration date indicated on the packaging. The official prescribing information, including detailed warnings, is available on the FDA label.

Frequently Asked Questions

1. What medical condition does Dynulta treat? Dynulta is used to lower serum phosphate levels in patients with chronic kidney disease, helping to prevent complications associated with hyperphosphatemia.
2. How should Dynulta tablets be taken? The recommended dosing is one tablet with each main meal, three times a day, unless a physician provides a different schedule based on laboratory results.
3. Can Dynulta interact with other medications? Yes, it may reduce the absorption of certain drugs such as some antibiotics and thyroid medications; a separation of at least two hours between Dynulta and these agents is advised.
4. Is Dynulta safe to use during pregnancy or breastfeeding? Human data are limited, and animal studies have not shown clear risk, but the medication should only be used if the potential benefit justifies the potential risk, and a healthcare professional must be consulted.
5. Where can I find the complete prescribing information for Dynulta? The FDA label and the product monograph provide comprehensive details on indications, dosing, contraindications, and safety considerations, and they are accessible online for patient reference.

Related Products

• Instgra 50 mg (Dolutegravir)
• Encicarb Injection (Ferric Carboxymaltose)
• Divret 1.5 mg (Indapamide)
• Axentri 150 mg (Maraviroc)
• Tavin EM 300 mg/200 mg (Tenofovir/Emtricitabine)
• Ferium Chewable (Iron Folic Acid)
• Atazor R (Atazanavir/Ritonavir)
• Abec-L (Abacavir/Lamivudine)
• Spegra Tablet
• A-Bec (Abacavir)
• Inbec 30 Mg (Abacavir/Dolutegravir/Lamivudine)
• Emletra (Lopinavir/Ritonavir)